$22.19
+0.12
(+0.54%)▲
2.28%
Downside
Day's Volatility :2.68%
Upside
0.41%
52.55%
Downside
52 Weeks Volatility :53.28%
Upside
1.55%
Period | Organon & Co. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 18.98% | 6.5% | 0.0% |
6 Months | 31.92% | 7.1% | 0.0% |
1 Year | -0.99% | 9.8% | 0.0% |
3 Years | -25.59% | 14.2% | -20.2% |
Market Capitalization | 5.5B |
Book Value | $0.19 |
Dividend Share | 1.12 |
Dividend Yield | 5.22% |
Earnings Per Share (EPS) | 4.08 |
PE Ratio | 5.26 |
Wall Street Target Price | 22.5 |
Profit Margin | 16.5% |
Operating Margin TTM | 25.52% |
Return On Assets TTM | 7.44% |
Return On Equity TTM | 0.0% |
Revenue TTM | 6.3B |
Revenue Per Share TTM | 24.84 |
Quarterly Revenue Growth YOY | 5.5% |
Gross Profit TTM | 3.9B |
EBITDA | 1.6B |
Diluted Eps TTM | 4.08 |
Quarterly Earnings Growth YOY | 0.13 |
EPS Estimate Current Year | 4.45 |
EPS Estimate Next Year | 4.6 |
EPS Estimate Current Quarter | 1.08 |
EPS Estimate Next Quarter | 1.13 |
What analysts predicted
Upside of 1.4%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 9.8B | ↓ 6.89% |
Net Income | 2.2B | ↑ 19.54% |
Net Profit Margin | 22.02% | ↑ 4.87% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 7.8B | ↓ 20.46% |
Net Income | 3.2B | ↑ 49.47% |
Net Profit Margin | 41.38% | ↑ 19.36% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 8.1B | ↑ 4.1% |
Net Income | 2.2B | ↓ 32.88% |
Net Profit Margin | 26.68% | ↓ 14.7% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 6.3B | ↓ 22.13% |
Net Income | 1.4B | ↓ 37.45% |
Net Profit Margin | 21.43% | ↓ 5.25% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.2B | ↓ 2.06% |
Net Income | 917.0M | ↓ 32.12% |
Net Profit Margin | 14.85% | ↓ 6.58% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 6.3B | ↑ 1.44% |
Net Income | 1.0B | ↑ 11.56% |
Net Profit Margin | 16.33% | ↑ 1.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↓ 3.38% |
Net Income | 108.0M | ↓ 52.42% |
Net Profit Margin | 7.27% | ↓ 7.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↑ 3.57% |
Net Income | 177.0M | ↑ 63.89% |
Net Profit Margin | 11.51% | ↑ 4.24% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.6B | ↑ 4.55% |
Net Income | 242.0M | ↑ 36.72% |
Net Profit Margin | 15.05% | ↑ 3.54% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5B | ↓ 5.53% |
Net Income | 58.0M | ↓ 76.03% |
Net Profit Margin | 3.82% | ↓ 11.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.6B | ↑ 5.2% |
Net Income | 546.0M | ↑ 841.38% |
Net Profit Margin | 34.17% | ↑ 30.35% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.6B | ↑ 1.5% |
Net Income | 201.0M | ↓ 63.19% |
Net Profit Margin | 12.39% | ↓ 21.78% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 10.5B | - |
Total Liabilities | 4.1B | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 10.5B | ↑ 0.51% |
Total Liabilities | 3.5B | ↓ 15.27% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 10.4B | ↓ 1.08% |
Total Liabilities | 11.3B | ↑ 220.35% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 10.7B | ↑ 2.37% |
Total Liabilities | 12.2B | ↑ 8.31% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 11.0B | ↑ 2.57% |
Total Liabilities | 11.8B | ↓ 2.81% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 12.1B | ↑ 10.07% |
Total Liabilities | 12.1B | ↑ 2.37% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 4.96% |
Total Liabilities | 11.8B | ↑ 2.99% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↓ 1.75% |
Total Liabilities | 11.5B | ↓ 2.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 2.01% |
Total Liabilities | 11.5B | ↑ 0.3% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 0.3% |
Total Liabilities | 11.6B | ↑ 0.58% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 12.1B | ↑ 9.5% |
Total Liabilities | 12.1B | ↑ 4.54% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 11.9B | ↓ 1.38% |
Total Liabilities | 11.8B | ↓ 2.35% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.7B | ↑ 7.84% |
Investing Cash Flow | -69.0M | ↑ 23.21% |
Financing Cash Flow | -4.2B | ↑ 23.49% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.8B | ↓ 24.95% |
Investing Cash Flow | -102.0M | ↑ 47.83% |
Financing Cash Flow | -2.6B | ↓ 37.06% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.2B | ↓ 20.96% |
Investing Cash Flow | -258.0M | ↑ 152.94% |
Financing Cash Flow | -2.2B | ↓ 17.02% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.5B | ↑ 12.39% |
Investing Cash Flow | -481.0M | ↑ 86.43% |
Financing Cash Flow | -1.3B | ↓ 38.71% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 858.0M | ↓ 65.09% |
Investing Cash Flow | -420.0M | ↓ 12.68% |
Financing Cash Flow | -433.0M | ↓ 67.52% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 267.0M | ↓ 15.77% |
Investing Cash Flow | -420.0M | ↑ 97.18% |
Financing Cash Flow | -82.0M | ↑ 6.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 114.0M | ↓ 57.3% |
Investing Cash Flow | -54.0M | ↓ 87.14% |
Financing Cash Flow | -326.0M | ↑ 297.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.0M | ↓ 76.32% |
Investing Cash Flow | -70.0M | ↑ 29.63% |
Financing Cash Flow | -88.0M | ↓ 73.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 261.0M | ↑ 866.67% |
Investing Cash Flow | -179.0M | ↑ 155.71% |
Financing Cash Flow | -78.0M | ↓ 11.36% |
Sell
Neutral
Buy
Organon & Co. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Organon & Co. | 6.98% | 31.92% | -0.99% | -25.59% | -38.69% |
![]() Eli Lilly And Company | -8.88% | 28.46% | 81.04% | 237.65% | 658.46% |
![]() Johnson & Johnson | 8.73% | 0.09% | -7.57% | -7.12% | 22.11% |
![]() Merck & Co. Inc. | -4.3% | 4.16% | 17.46% | 62.93% | 54.55% |
![]() Abbvie Inc | 6.44% | 10.81% | 28.38% | 54.66% | 168.85% |
![]() Amgen Inc. | 6.87% | 7.23% | 42.13% | 36.4% | 90.66% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Organon & Co. | 5.26 | 5.26 | NA | 4.45 | 0.0 | 0.07 | 0.05 | 0.19 |
![]() Eli Lilly And Company | 129.92 | 129.92 | 1.43 | 13.75 | 0.51 | 0.13 | 0.01 | 14.23 |
![]() Johnson & Johnson | 23.93 | 23.93 | 0.89 | 10.01 | 0.24 | 0.08 | 0.03 | 29.09 |
![]() Merck & Co. Inc. | 141.48 | 141.48 | 0.1 | 8.16 | 0.05 | 0.1 | 0.02 | 15.94 |
![]() Abbvie Inc | 52.29 | 52.29 | 0.45 | 9.93 | 0.56 | 0.08 | 0.04 | 4.54 |
![]() Amgen Inc. | 47.88 | 47.88 | 2.39 | 17.96 | 0.73 | 0.05 | 0.03 | 9.36 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Organon & Co. | Buy | $5.5B | -38.69% | 5.26 | 16.5% |
![]() Eli Lilly And Company | Buy | $790.8B | 658.46% | 129.92 | 17.08% |
![]() Johnson & Johnson | Buy | $376.1B | 22.11% | 23.93 | 43.91% |
![]() Merck & Co. Inc. | Buy | $318.9B | 54.55% | 141.48 | 3.76% |
![]() Abbvie Inc | Buy | $311.2B | 168.85% | 52.29 | 11.02% |
![]() Amgen Inc. | Buy | $180.0B | 90.66% | 47.88 | 12.74% |
Insights on Organon & Co.
Revenue is up for the last 3 quarters, 1.51B → 1.62B (in $), with an average increase of 3.2% per quarter
Netprofit is down for the last 2 quarters, 546.0M → 201.0M (in $), with an average decrease of 63.2% per quarter
In the last 1 year, Eli Lilly And Company has given 81.0% return, outperforming this stock by 82.0%
In the last 3 years, Eli Lilly And Company has given 237.6% return, outperforming this stock by 263.2%
BlackRock Inc
Vanguard Group Inc
Massachusetts Financial Services Company
State Street Corporation
Slate Path Capital LP
Morgan Stanley - Brokerage Accounts
In the quarter ending March,2024. Organon & Co. has declared dividend of $0.28
Read Moreorganon is a dutch pharmaceutical company started in oss the netherlands. it is famous for "the pil" a birthcontrol pil. organon grew as a company and was taken over by schering plough and later on by merck and continues as msd in the netherlands. in the old days the compant was great, it used to be "gezellig" !
Organization | Organon & Co. |
Employees | 10000 |
CEO | Mr. Kevin Ali |
Industry | Healthcare |